Adaptimmune Therapeutics CEO Adrian Rawcliffe's 2021 pay jumps 56% to $4.2M
Adaptimmune Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 21, 2022
Adaptimmune Therapeutics reported fiscal year 2021 executive compensation information on April 21, 2022.
In 2021, five executives at Adaptimmune Therapeutics received on average a compensation package of $2.2M, a 27% increase compared to previous year.
Average pay of disclosed executives at Adaptimmune Therapeutics
Adrian Rawcliffe, Chief Executive Officer, received $4.2M in total, which increased by 56% compared to 2020. 76% of Rawcliffe's compensation, or $3.2M, was in option awards. Rawcliffe also received $352K in non-equity incentive plan, $617K in salary, as well as $39K in other compensation.
For fiscal year 2021, the median employee pay was $126,493 at Adaptimmune Therapeutics. Therefore, the ratio of Adrian Rawcliffe's pay to the median employee pay was 33 to one.
Helen Tayton-Martin, Chief Business Officer, received a compensation package of $1.8M, which increased by 14% compared to previous year. 60% of the compensation package, or $1.1M, was in option awards.
William Bertrand, Chief Operating Officer, earned $1.8M in 2021, a 13% increase compared to previous year.
Gavin Wood, Chief Financial Officer, received $1.8M in 2021, which increases by 12% compared to 2020.
John Lunger, Chief Operating Officer, earned $1.7M in 2021, a 15% increase compared to previous year.
Related executives
Adrian Rawcliffe
Adaptimmune Therapeutics
Chief Executive Officer
Gavin Wood
Adaptimmune Therapeutics
Chief Financial Officer
Helen Tayton-Martin
Adaptimmune Therapeutics
Chief Business Officer
William Bertrand
Adaptimmune Therapeutics
Chief Operating Officer
John Lunger
Adaptimmune Therapeutics
Chief Operating Officer
You may also like
Source: SEC filing on April 21, 2022.